Fig. 3

Cysteamine treatment lowers SST levels and prevents Hebbian LTP. a Representative images (left) and summary bar graph (right) showing reduction of SST immunofluorescence in eYFP-expressing SOM-INs after cysteamine injection (vehicle n = 3 mice, cysteamine n = 3 mice, unpaired t-test p = 0.047). b EPSPs from representative cells (top) and summary time plots of EPSPs (bottom), showing LTP induced by TBS in vehicle injected mice (filled blue square), and absence of LTP (but EPSP depression) in cysteamine injected mice (open blue circle). For vehicle group, n = 11 cells and 8 mice, rmANOVA, Dunnett’s multiple comparisons (15–20 min p = 0.028, 20–25 min p = 0.016, 25–30 min p = 0.0007). For cysteamine group, n = 11 cells and 6 mice, rmANOVA, Dunnett’s multiple comparisons (15–20 min p = 0.040, 20–25 min p = 0.026, 25–30 min p = 0.005). c Summary bar graph, showing absence of LTP at 25–30 min after TBS in cysteamine injected mice (two-way mixed ANOVA with univariate analysis of variance, p < 0.0001). d–f Similar data presentation showing effects of incubation for one hour of slices with cysteamine. (d) Cysteamine treatment reduces SST immunofluorescence in SOM-INs (vehicle n = 4 mice, cysteamine n = 4 mice, unpaired t-test p = 0.029). (e) Cysteamine treatment prevents TBS induction of LTP. For vehicle group, n = 9 cells and 7 mice, rmANOVA, Dunnett’s multiple comparisons (10–15 min p = 0.027, 15–20 min p = 0.008, 25–30 min p = 0.027). For cysteamine group, n = 12 cells and 7 mice, rmANOVA p = 0.097. (f) Summary bar graph showing absence of LTP after cysteamine treatment (two-way mixed ANOVA with univariate analysis of variance, 25–30 min p = 0.0001). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant